August 15, 2018
Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer
US Oncology Research will open 10 clinical trial sites, enrolling patients in Novocure’s PANOVA-3 trial to test the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer ST. HELIER, Jersey & THE WOODLANDS, Texas–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) and… Read More
learn more
August 3, 2018
Novocure to Present at Two Upcoming Investor Conferences
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences. Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in the 2018 Wedbush PacGrow Healthcare Conference on Aug. 15, 2018, in New York City. Mr. Groenhuysen’s presentation will begin at 12:45… Read More
learn more
August 2, 2018
Novocure Announces Addition to Its Board of Directors
Jeryl Hilleman, Chief Financial Officer of Intersect ENT, elected to board of directors ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure’s board in July 2018. “We are… Read More
learn more